ArticleBJC reports2024

Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.

Eylül Özgü et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.